ESMO 2023 | The future of BiTEs and ImmTACs in melanoma and beyond

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, provides an overview of advances in immunotherapies for melanoma, such as bi-specific T cell engaging antibodies (BiTEs) and immune-mobilising monoclonal TCRs against cancer (ImmTACs). ImmTACs have been promising in targeting gp100 and PRAME in ocular and cutaneous melanoma. Tebentafusp has additionally been shown to improve survival in uveal melanoma. Dr Hamid also comments on fusion protein carriers targeting CTLA and PD-L1. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.